Microbix Presenting at the 2026 Bloom Burton Conference

About this update from Microbix Biosystems Inc.

Microbix Presenting at the 2026 Bloom Burton ConferenceMISSISSAUGA, ON / ACCESS Newswire / April 16, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the 2026 Bloom Burton & Co. Healthcare Investor Conference (the "Conference") taking place at the Metro Toronto Convention Centre, North Building, on April 21 and 22, 2026.The Conference provides Microbix the opportunity to build connections with Canadian, U.S., and international investors focused on the latest developments in the Canadian healthcare and life sciences sector. Microbix's COO, Dr. Ken Hughes, will make an in-person group presentation to investors on Wednesday, April 22 at 2:00 p.m. Eastern Time. Additionally, Ken, Microbix's CFO, Jim Currie, and investor relations representative, Deborah Honig, will participate in many one-on-one meetings with investors at the Conference. The Microbix presentation slides will be available for download at https://microbix.com.About Bloom Burton & Co.Bloom Burton & Co. is dedicated to accelerating returns in the healthcare sector for both investors and companies. It has an experienced team of medical, scientific, industry, and capital markets professionals who perform a deep level of diligence, which combined with its creative and entrepreneurial approach, assists its clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation & incubation services. Bloom Burton Securities Inc. is regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF).About Microbix Biosystems Inc.Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its latest fiscal year (2025). It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. ...

View stock analysis, news, and events for Microbix Biosystems Inc.